Evidence map›Paper›PMID 17522506›Full record

Trial reportAnnals of surgery2007

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Chung Mau Lo, Chi Leung Liu, See Ching Chan, Chi Ming Lam, Ronnie T P Poon, Irene O L Ng, Sheung Tat Fan, John Wong

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01681446 (The Effect of Postoperative Interferon-alpha Treatment in Patients Underwent Curative Surgery for Hepatocellular Carcinoma With a Low miR-26 Expression), which is not on this map. Cited by 89 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 13 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01681446 phase3unknown statusnot on this mapstarted 2012, after this paper: background citation

The Effect of Postoperative Interferon-alpha Treatment in Patients Underwent Curative Surgery for Hepatocellular Carcinoma With a Low miR-26 Expression: a Multi-center Randomized Clinical Trial.

TypeinterventionalSponsorFudan UniversityRan2012 to 2019Enrolled296ConditionsHepatocellular CarcinomaArmsinterferon-alpha (IFN-alpha)
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 13 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. [Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chung Mau LoCentre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. chungmlo@hkucc.hku.hk
Chi Leung Liu
See Ching Chan
Chi Ming Lam
Ronnie T P Poon
Irene O L Ng
Sheung Tat Fan
John Wong
University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be improved. SUMMARY BACKGROUND DATA: Recurrence is common after hepatic resection for HCC. Interferon possesses antiviral, immunomodulatory, antiproliferative, and antiangiogenic effects and may be an effective form of adjuvant therapy. PATIENTS AND

methodsSince February 1999, patients with no residual disease after hepatic resection for HCC were randomly assigned with stratification by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m (IFN-I group) or 30 MIU/m (IFN-II group) thrice weekly for 16 weeks. Enrollment to the IFN-II group was terminated from January 2000 because adverse effects resulted in treatment discontinuation in the first 6 patients. By June 2002, 40 patients each had been enrolled into the control group and IFN-I group. The baseline clinical, laboratory, and tumor characteristics of both groups were comparable.

resultsThe 1- and 5-year survival rates were 85% and 61%, respectively, for the control group and 97% and 79%, respectively, for the IFN-I group (P = 0.137). After adjusting for the confounding prognostic factors in a Cox model, the relative risk of death for interferon treatment was 0.42 (95% CI, 0.17-1.05; P = 0.063). Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM stage I/II tumor (5-year survival 90% in both groups; P = 0.917) but prevented early recurrence and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68% (P = 0.038).

conclusionIn a group of patients with predominantly hepatitis B-related HCC, adjuvant interferon therapy showed a trend for survival benefit, primarily in those with pTNM stage III/IVA tumors. Further larger randomized trials stratified for stage are needed.

Indexed as

AdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyFemaleHepatectomyHepatitis BHumansInterferon-alphaInterferon alpha-2Liver NeoplasmsMaleMiddle AgedAntineoplastic AgentsInterferon-alphaInterferon alpha-2Recombinant Proteins

Identifiers

PMID17522506
PMCPMC1876947
OpenAlexW1973799102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.